Corporate Communications:
Dr. Lise Hébert
(450) 680-4500
Toll free (877) 680-4500
If you need additional assistance or information regarding the company, please
send an Email to:
webinfo@neurochem.com.
November 16, 2006
- Neurochem Announces Initial Purchaser's Exercise of Over-Allotment Option for the Purchase of Senior Convertible
Notes
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - announced today that it will issue to UBS Securities LLC on or about November
17, 2006, an additional US$2.085 million aggregate principal amount...
(learn more by clicking here)
November 9, 2006
- Neurochem Announces Closing of Private Placement of US$40 Million Aggregate Principal Amount of 6% Senior Convertible
Notes with a Conversion Premium of 20%
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - announced today the closing of its previously announced private placement
with UBS Securities LLC as initial purchaser, of US$40 million...
(learn more by clicking here)
November 8, 2006
- Neurochem reports results for third quarter of fiscal 2006
Neurochem will host a conference call on Thursday, November 9, 2006, at 8:30 A.M. ET.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - reported results for the third quarter ended September 30, 2006. The Company
reported a net loss of $18,520,000 ($0.48 per share), compared...
(learn more by clicking here)
November 7, 2006
- Neurochem to report on third quarter of fiscal 2006
Neurochem will host a conference call Thursday, November 9, 2006, at 8:30 A.M. ET
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - announces that it will release its results for the third quarter of fiscal
2006, ended September 30, tomorrow, after market close.
(learn more by clicking here)
November 6, 2006
- Neurochem receives recommendations from Data Safety Monitoring Boards to continue Phase III clinical trials for
tramiprosate (ALZHEMED™)
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - announces that it has received recommendations from both the North American and
European Data Safety Monitoring Boards (DSMB) to continue its...
(learn more by clicking here)
November 3, 2006
- Neurochem announces private placement of US$40 million aggregate principal amount of 6% senior convertible notes
with a conversion premium of 20%
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - announced today a private placement of US$40 million aggregate principal amount of
6% senior convertible notes due in 2026, with a conversion...
(learn more by clicking here)
November 3, 2006
- Neurochem to present at upcoming healthcare conferences
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - announced today that on Monday, November 6, 2006, Dr. Francesco Bellini, Chairman,
President and CEO, will present Neurochem's overall...
(learn more by clicking here)
November 2, 2006
- Tramiprosate (Alzhemed™) Phase II clinical results published in Neurology
Tramiprosate (ALZHEMED™) Currently in Large Phase III Clinical Trials in North America and Europe
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - is pleased to announce that Neurology, a worldwide, leading, peer-reviewed,
medical journal in the field of neurology, has published today an...
(learn more by clicking here)
October 16, 2006
- Neurochem submits a complete response to FDA for approvable letter for KIACTA™
Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces
today that it has submitted a complete response to...
(learn more by clicking here)
September 28, 2006
- Neurochem Marketing Authorization Application for Kiacta™ accepted for review by EMEA
Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM), announces
today that its Marketing Authorization Application...
(learn more by clicking here)
September 21, 2006
- Neurochem to present at UBS Global Life Sciences Conference
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - announced today that on Tuesday, September 26, 2006, Dr. Francesco Bellini,
Chairman, President and Chief Executive Officer, will present...
(learn more by clicking here)
August 18, 2006
- Neurochem announces resignation of a Director
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - announced today that Mr. Ronald Nordmann has resigned from the Company's
Board of Directors. Mr. Nordmann joined the Board in 2002...
(learn more by clicking here)
August 11, 2006
- Neurochem receives approvable letter for eprodisate (Kiacta™) for treatment of AA amyloidosis
Neurochem will host a conference call on August 14, 2006,
at 8:30 A.M. ET
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - announces that it has received an approvable letter from the U.S. Food and
Drug Administration (FDA) for eprodisate (Kiacta™ - formerly...
(learn more by clicking here)
August 9, 2006
- Neurochem reports results for second quarter and fiscal 2006
Announces Equity Line of Credit Facility
Neurochem will host a conference call today, August 9, 2006, at 5:00 P.M. ET.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - reported results for the second quarter ended June 30, 2006. The Company
reported a net loss of $20,374,000 ($0.53 per share), compared...
(learn more by clicking here)
August 9, 2006
- Neurochem to report on second quarter 2006
Neurochem will host a conference call Wednesday, Aug. 9, 2006, at 5:00 P.M. ET
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - announces that it will release its results for the second quarter of fiscal
2006, today, after the close of market...
(learn more by clicking here)
June 22, 2006
- Eprodisate (Fibrillex™) data presented at the meeting of the European League Against Rheumatism (Eular)
Dr. Hazenberg receives prestigious award on behalf of eprodisate (Fibrillex™) Study Group
Amsterdam (Netherlands) - Results from Neurochem's (NASDAQ: NRMX; TSX: NRM) two-year Phase II/III clinical trial for
eprodisate (Fibrillex™), its investigational product candidate for the...
(learn more by clicking here)
June 12, 2006
- Neurochem announces award denying majority of Immtech's claims
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that an arbitral tribunal (the "Tribunal") of the
International Chamber of Commerce Court of Arbitration (the "ICC") has issued its Final...
(learn more by clicking here)
May 30, 2006
- Tramiprosate (Alzhemed™) preclinical results published in Neurobiology of Aging
Tramiprosate (Alzhemed™) currently in large Phase III clinical trials in North America and Europe
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) is pleased to announce that Neurobiology of Aging, one of the world’s
leading peer-reviewed medical journals in the fields of gerontology and...
(learn more by clicking here)
May 9, 2006
- Neurochem reports results for first quarter of fiscal 2006
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - reported results for the first quarter ended March 31, 2006. The Company
reported a net loss of $17,134,000 ($0.45 per share) for the quarter...
(learn more by clicking here)
May 9, 2006
- At Annual General Meeting of Shareholders
Neurochem highlights important developments for key
product candidates
The Company Announces New Appointments
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - At its annual general meeting of shareholders, Neurochem Inc.
(NASDAQ: NRMX; TSX: NRM) highlighted important developments for its...
(learn more by clicking here)
April 24, 2006
- Neurochem presents an update on tramiprosate (Alzhemed™) program for the treatment of Alzheimer's disease at 9th
International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) - Paul S. Aisen, M.D., Professor of Neurology and Medicine at Georgetown
University Medical Center, and principal investigator in the United...
(learn more by clicking here)
April 20, 2006
- Neurochem to present at UBS Global Speciality pharmaceuticals conference at 6th annual fortis bank biotechnology
conference.
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced that on Tuesday, April 25, 2006, Dr. Francesco Bellini, Chairman,
President and CEO, will present Neurochem's overall strategy...
(learn more by clicking here)
April 18, 2006
- Neurochem announces eprodisate (Fibrillex™) NDA filed and granted priority review by the FDA for the treatment
of AA amyloidosis
Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) is
pleased to announce today that the new drug application (NDA)...
(learn more by clicking here)
March 30, 2006
- Neurochem to present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that on Tuesday, April 4, 2006, Dr. Francesco Bellini,
Chairman, President and CEO, will present Neurochem's overall strategy...
(learn more by clicking here)
February 23, 2006
- Neurochem reports results for fourth quarter and fiscal year 2005
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) reported results for the fourth quarter and fiscal year ended December 31,
2005. The Company reported a net loss of $15.6 million ($0.42 per share)...
(learn more by clicking here)
February 23, 2006
- Neurochem to report on fourth quarter and fiscal year 2005
Neurochem will host a conference call Friday, February 24, 2006, at 8:30 A.M. ET
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces that it will release its results for the fourth quarter and fiscal
year 2005, today, after the close of market.
(learn more by clicking here)
February 21, 2006
- Neurochem receives fourth recommendation from Independent Safety Review Board for Alzhemed™
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that its Independent Safety Review Board (ISRB) has issued a
fourth recommendation to continue the Company's North...
(learn more by clicking here)
February 16, 2006
- Neurochem Inc. announces exercise of warrant by Picchio Pharma
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today that a subsidiary of Picchio Pharma Inc. (Picchio Pharma) has
exercised a warrant previously issued under a February 2003...
(learn more by clicking here)
February 13, 2006
- Neurochem submits NDA for Fibrillex™
Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX; TSX: NRM),
announces today that the Company has submitted to the U.S...
(learn more by clicking here)
February 8, 2006
- Neurochem announces the initiation of an open-label phase III extension study for Alzhemed™ in North America
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announced today its decision to initiate an 18-month open-label extension
study for its ongoing North American Phase III clinical trial for Alzhemed™...
(learn more by clicking here)
|
